Par Pharmaceutical

Par Pharmaceutical, headquartered in Chestnut Ridge, NY, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life. Par offers differentiated, specialty dosage and sterile injectable drug products and is advancing a R&D pipeline of potential new products.

The recent combination of the Qualitest and Par businesses (known collectively as Par Pharmaceutical) expands Endo's generics business to a top five industry leader. Par Pharmaceutical is an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL), a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value.

Parent Company
Endo International
Chestnut Ridge, US
Par Pharmaceutical was founded in 1978 and is headquartered in Chestnut Ridge, US

Par Pharmaceutical Office Locations

Par Pharmaceutical has an office in Chestnut Ridge
Chestnut Ridge, US (HQ)
1 Ram Ridge Rd

Par Pharmaceutical Metrics

Par Pharmaceutical Summary

Founding Date

Par Pharmaceutical is a subsidiary of Endo International

Par Pharmaceutical Financial Metrics

Par Pharmaceutical's revenue was reported to be $246.1 m in FY, 2014
FY, 2013FY, 2014


$246.1 m$246.1 m

Revenue growth, %

Operating expense total

$75.2 m$75.2 m


($29.8 m)($29.8 m)

EBIT margin, %


Interest expense

$26 m$26 m

Interest income

$50 k$50 k

Income tax expense

($17.7 m)($17.7 m)

Net Income

($32.5 m)($32.5 m)
FY, 2013FY, 2014


$130.1 m$244.4 m

Accounts Receivable

$143.3 m$158.7 m


$117.3 m$154.7 m

Current Assets

$465.6 m$653.1 m


$127.3 m$217.3 m


$849.7 m$1 b

Total Assets

$2.6 b$3 b

Accounts Payable

$31.2 m$80 m

Current Liabilities

$259 m$277.8 m

Additional Paid-in Capital

$686.6 m$808.6 m

Retained Earnings

($138.4 m)($243.9 m)

Total Equity

$547.4 m$561.1 m

Financial Leverage

4.8 x5.4 x
FY, 2013FY, 2014

Net Income

($32.5 m)($32.5 m)

Depreciation and Amortization

$50.3 m$50.3 m

Accounts Receivable

($42 m)($42 m)


Accounts Payable

Cash From Operating Activities

($28.6 m)($28.6 m)

Capital Expenditures

($10.3 m)($10.3 m)

Cash From Investing Activities

($2 b)($2 b)

Cash From Financing Activities

$1.8 b$1.8 b

Interest Paid

$14 m$14 m

Free Cash Flow

($18.3 m)($18.3 m)

Par Pharmaceutical News

Par Pharmaceutical Company Life

You may also be interested in